BRAF and melanoma: In a multi-institutional phase 2 study, 540 melanoma patients with disease that had progressed following ipilimumab and BRAF/MEK inhibitor therapy, if their tumors harbored a BRAF (V600) mutation, were randomized 1:1:1 to treatment with pembrolizumab at 2 mg/kg every 3 weeks (N = 180), 10 mg/kg every 3weeks (N = 181) or investigator-choice chemotherapy (N = 179) [62].